Acido ibandronico (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Acido ibandronico" in Italian language version.

refsWebsite

Global rank Italian rank

14nih.gov

4^th place

9^th place

7oadoi.org

799^th place

22^nd place

7doi.org

2^nd place

7^th place

doi.org

dx.doi.org

RC. Mühlbauer, F. Bauss; R. Schenk; M. Janner; E. Bosies; K. Strein; H. Fleisch, BM 21.0955, a potent new bisphosphonate to inhibit bone resorption., in J Bone Miner Res, vol. 6, n. 9, Sep 1991, pp. 1003-11, DOI:10.1002/jbmr.5650060915, PMID 1838661.
T. Yoneda, A. Sasaki; C. Dunstan; PJ. Williams; F. Bauss; YA. De Clerck; GR. Mundy, Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2., in J Clin Invest, vol. 99, n. 10, maggio 1997, pp. 2509-17, DOI:10.1172/JCI119435, PMID 9153295.
N. Pavlakis, R. Schmidt; M. Stockler, Bisphosphonates for breast cancer., in Cochrane Database Syst Rev, n. 3, 2005, pp. CD003474, DOI:10.1002/14651858.CD003474.pub2, PMID 16034900.
HJ. Deuber, F. Theiss, [Bisphosphonates in adjuvant therapy of breast cancer]., in Med Klin (Munich), vol. 105, n. 9, Sep 2010, pp. 635-46, DOI:10.1007/s00063-010-1103-x, PMID 20878301.
EY. Pyon, Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen., in Clin Ther, vol. 28, n. 4, Apr 2006, pp. 475-90, DOI:10.1016/j.clinthera.2006.04.006, PMID 16750461.
M. Rossini, O. Viapiana; D. Gatti; S. Adami, Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review., in Clin Ther, vol. 31, n. 7, Jul 2009, pp. 1497-510, DOI:10.1016/j.clinthera.2009.07.018, PMID 19695399.
I. Weber, A. Olaiwan; I. Bonte; C. Artigou; V. Pras-Landre; P. Moguelet; C. Frances; C. Pecquet, Adverse cutaneous drug reactions to ibandronate., in Eur J Dermatol, vol. 21, n. 4, pp. 591-4, DOI:10.1684/ejd.2011.1386, PMID 21700532.

nih.gov

ncbi.nlm.nih.gov

RC. Mühlbauer, F. Bauss; R. Schenk; M. Janner; E. Bosies; K. Strein; H. Fleisch, BM 21.0955, a potent new bisphosphonate to inhibit bone resorption., in J Bone Miner Res, vol. 6, n. 9, Sep 1991, pp. 1003-11, DOI:10.1002/jbmr.5650060915, PMID 1838661.
HW. Woitge, H. Oberwittler; S. Heichel; A. Grauer; R. Ziegler; MJ. Seibel, Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone., in Clin Chem, vol. 46, n. 5, maggio 2000, pp. 684-90, PMID 10794751.
T. Yoneda, A. Sasaki; C. Dunstan; PJ. Williams; F. Bauss; YA. De Clerck; GR. Mundy, Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2., in J Clin Invest, vol. 99, n. 10, maggio 1997, pp. 2509-17, DOI:10.1172/JCI119435, PMID 9153295.
P. Burckhardt, Ibandronate in oncology., in Cancer, vol. 80, 8 Suppl, Oct 1997, pp. 1696-8, PMID 9362439.
N. Pavlakis, R. Schmidt; M. Stockler, Bisphosphonates for breast cancer., in Cochrane Database Syst Rev, n. 3, 2005, pp. CD003474, DOI:10.1002/14651858.CD003474.pub2, PMID 16034900.
M. Dooley, JA. Balfour, Ibandronate., in Drugs, vol. 57, n. 1, Jan 1999, pp. 101-8; discussion 109-10, PMID 9951955.
HJ. Deuber, F. Theiss, [Bisphosphonates in adjuvant therapy of breast cancer]., in Med Klin (Munich), vol. 105, n. 9, Sep 2010, pp. 635-46, DOI:10.1007/s00063-010-1103-x, PMID 20878301.
P. Ravn, Bisphosphonates for prevention of postmenopausal osteoporosis., in Dan Med Bull, vol. 49, n. 1, Feb 2002, pp. 1-18, PMID 11894721.
JY. Reginster, Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review., in Curr Pharm Des, vol. 11, n. 28, 2005, pp. 3711-28, PMID 16305506.
EY. Pyon, Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen., in Clin Ther, vol. 28, n. 4, Apr 2006, pp. 475-90, DOI:10.1016/j.clinthera.2006.04.006, PMID 16750461.
M. Rossini, O. Viapiana; D. Gatti; S. Adami, Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review., in Clin Ther, vol. 31, n. 7, Jul 2009, pp. 1497-510, DOI:10.1016/j.clinthera.2009.07.018, PMID 19695399.
PD. Papapetrou, Bisphosphonate-associated adverse events., in Hormones (Athens), vol. 8, n. 2, pp. 96-110, PMID 19570737.
I. Weber, A. Olaiwan; I. Bonte; C. Artigou; V. Pras-Landre; P. Moguelet; C. Frances; C. Pecquet, Adverse cutaneous drug reactions to ibandronate., in Eur J Dermatol, vol. 21, n. 4, pp. 591-4, DOI:10.1684/ejd.2011.1386, PMID 21700532.
IJ. Diel, R. Bergner; KA. Grötz, Adverse effects of bisphosphonates: current issues., in J Support Oncol, vol. 5, n. 10, pp. 475-82, PMID 18240669.

oadoi.org

RC. Mühlbauer, F. Bauss; R. Schenk; M. Janner; E. Bosies; K. Strein; H. Fleisch, BM 21.0955, a potent new bisphosphonate to inhibit bone resorption., in J Bone Miner Res, vol. 6, n. 9, Sep 1991, pp. 1003-11, DOI:10.1002/jbmr.5650060915, PMID 1838661.
T. Yoneda, A. Sasaki; C. Dunstan; PJ. Williams; F. Bauss; YA. De Clerck; GR. Mundy, Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2., in J Clin Invest, vol. 99, n. 10, maggio 1997, pp. 2509-17, DOI:10.1172/JCI119435, PMID 9153295.
N. Pavlakis, R. Schmidt; M. Stockler, Bisphosphonates for breast cancer., in Cochrane Database Syst Rev, n. 3, 2005, pp. CD003474, DOI:10.1002/14651858.CD003474.pub2, PMID 16034900.
HJ. Deuber, F. Theiss, [Bisphosphonates in adjuvant therapy of breast cancer]., in Med Klin (Munich), vol. 105, n. 9, Sep 2010, pp. 635-46, DOI:10.1007/s00063-010-1103-x, PMID 20878301.
EY. Pyon, Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen., in Clin Ther, vol. 28, n. 4, Apr 2006, pp. 475-90, DOI:10.1016/j.clinthera.2006.04.006, PMID 16750461.
M. Rossini, O. Viapiana; D. Gatti; S. Adami, Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review., in Clin Ther, vol. 31, n. 7, Jul 2009, pp. 1497-510, DOI:10.1016/j.clinthera.2009.07.018, PMID 19695399.
I. Weber, A. Olaiwan; I. Bonte; C. Artigou; V. Pras-Landre; P. Moguelet; C. Frances; C. Pecquet, Adverse cutaneous drug reactions to ibandronate., in Eur J Dermatol, vol. 21, n. 4, pp. 591-4, DOI:10.1684/ejd.2011.1386, PMID 21700532.